Lenvatinib Delays Thyroid Cancer Progression
Josh Kremer, MD, vice president of clinical development at Eisai, Inc, discusses results of the phase III SELECT trial, which studied lenvatinib in radioiodine-refractory differentiated thyroid cancer.
In this video, Josh Kremer, MD, vice president of clinical development at Eisai, Inc, discusses results of the phase III SELECT trial, which found that lenvatinib extends progression-free survival in patients with radioiodine-refractory differentiated thyroid cancer from 3.6 months to 18.3 months. Dr. Kremer discusses where the drug falls in the current armamentarium for thyroid cancer treatment, and what other trial programs are currently underway for lenvatinib.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
